| MeSH term | MeSH ID | Detail |
|---|---|---|
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Angiomatosis, Bacillary | D016917 | 2 associated lipids |
| Meningitis, Bacterial | D016920 | 6 associated lipids |
| Common Variable Immunodeficiency | D017074 | 4 associated lipids |
| AIDS-Related Opportunistic Infections | D017088 | 9 associated lipids |
| IgA Deficiency | D017098 | 2 associated lipids |
| Liver Failure, Acute | D017114 | 11 associated lipids |
| Skin Diseases, Bacterial | D017192 | 8 associated lipids |
| Dermatitis, Phototoxic | D017484 | 4 associated lipids |
| Pityriasis Rosea | D017515 | 3 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
| Periodontal Attachment Loss | D017622 | 7 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Carcinoma, Lewis Lung | D018827 | 22 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Tooth, Nonvital | D019553 | 2 associated lipids |
| alpha 1-Antitrypsin Deficiency | D019896 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
| Epilepsy, Partial, Motor | D020938 | 1 associated lipids |
| Chlamydophila Infections | D023521 | 4 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Plaque, Atherosclerotic | D058226 | 7 associated lipids |
| Sacroiliitis | D058566 | 1 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- Clin. Infect. Dis. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sato T et al. | In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. | 2011 | Antimicrob. Agents Chemother. | pmid:21220530 |
| Nilius AM et al. | Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. | 2001 | Antimicrob. Agents Chemother. | pmid:11408246 |
| Hamasuna R et al. | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. | 2009 | Antimicrob. Agents Chemother. | pmid:19738019 |
| Odenholt-Tornqvist I et al. | Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. | 1995 | Antimicrob. Agents Chemother. | pmid:7695310 |
| Rodvold KA et al. | Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. | 1997 | Antimicrob. Agents Chemother. | pmid:9174209 |
| Giacometti A et al. | In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. | 2007 | Antimicrob. Agents Chemother. | pmid:17220421 |
| Ishida K et al. | In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. | 1994 | Antimicrob. Agents Chemother. | pmid:8031048 |
| Bax HI et al. | Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro. | 2016 | Antimicrob. Agents Chemother. | pmid:26883697 |
| Aziz DB et al. | Rifabutin Is Active against Mycobacterium abscessus Complex. | 2017 | Antimicrob. Agents Chemother. | pmid:28396540 |
| Jordan MK et al. | Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. | 2000 | Antimicrob. Agents Chemother. | pmid:10898693 |
| Kato M et al. | Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. | 2000 | Antimicrob. Agents Chemother. | pmid:10898707 |
| Xu YF et al. | and Antibacterial Activities of Patchouli Alcohol, a Naturally Occurring Tricyclic Sesquiterpene, against Helicobacter pylori Infection. | 2017 | Antimicrob. Agents Chemother. | pmid:28320722 |
| Geng X et al. | The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. | 2017 | Antimicrob. Agents Chemother. | pmid:28242673 |
| Waites KB et al. | In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. | 1988 | Antimicrob. Agents Chemother. | pmid:2973283 |
| Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
| Pankuch GA et al. | MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. | 1996 | Antimicrob. Agents Chemother. | pmid:8878583 |
| Chang HR and Pechère JC | In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. | 1988 | Antimicrob. Agents Chemother. | pmid:2837140 |
| Wakabayashi H et al. | Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. | 2009 | Antimicrob. Agents Chemother. | pmid:19451301 |
| Kim IS et al. | Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. | 2007 | Antimicrob. Agents Chemother. | pmid:17116681 |
| Morikawa K et al. | Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. | 1994 | Antimicrob. Agents Chemother. | pmid:7532933 |
| Ednie LM et al. | Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. | 1996 | Antimicrob. Agents Chemother. | pmid:8843313 |
| Goldman RC et al. | Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. | 1994 | Antimicrob. Agents Chemother. | pmid:7979278 |
| Roblin PM et al. | Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. | 1994 | Antimicrob. Agents Chemother. | pmid:7979292 |
| Bui KQ et al. | Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. | 1999 | Antimicrob. Agents Chemother. | pmid:10471584 |
| Gorzynski EA et al. | Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. | 1989 | Antimicrob. Agents Chemother. | pmid:2524998 |
| Nash KA and Inderlied CB | Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. | 1996 | Antimicrob. Agents Chemother. | pmid:8807078 |
| Chan GP et al. | Clinical trial of clarithromycin for lepromatous leprosy. | 1994 | Antimicrob. Agents Chemother. | pmid:8203847 |
| Onyeji CO et al. | Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages. | 1994 | Antimicrob. Agents Chemother. | pmid:8203849 |
| Kamoda O et al. | In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection. | 2006 | Antimicrob. Agents Chemother. | pmid:16940102 |
| Fernandes PB et al. | New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. | 1989 | Antimicrob. Agents Chemother. | pmid:2523688 |
| Sassa K et al. | Differential modulatory effects of clarithromycin on the production of cytokines by a tumor. | 1999 | Antimicrob. Agents Chemother. | pmid:10543765 |
| Tateda K et al. | Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891128 |
| Fernandes PB et al. | In vitro and in vivo activities of clarithromycin against Mycobacterium avium. | 1989 | Antimicrob. Agents Chemother. | pmid:2530933 |
| Kohno Y et al. | Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. | 1989 | Antimicrob. Agents Chemother. | pmid:2526615 |
| Rimbara E et al. | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. | 2008 | Antimicrob. Agents Chemother. | pmid:18606842 |
| Bolhuis MS et al. | Clarithromycin significantly increases linezolid serum concentrations. | 2010 | Antimicrob. Agents Chemother. | pmid:20837753 |
| Jesus FP et al. | In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25001300 |
| Khan R et al. | T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh. | 2004 | Antimicrob. Agents Chemother. | pmid:15328128 |
| Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
| Credito KL et al. | Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. | 1999 | Antimicrob. Agents Chemother. | pmid:10428930 |
| Fong IW et al. | Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. | 2002 | Antimicrob. Agents Chemother. | pmid:12121899 |
| Horgen L et al. | Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. | 1998 | Antimicrob. Agents Chemother. | pmid:9797242 |
| Phillips RO et al. | Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. | 2014 | Antimicrob. Agents Chemother. | pmid:24323473 |
| Tsaganos T et al. | Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. | 2016 | Antimicrob. Agents Chemother. | pmid:27044546 |
| Bermudez LE et al. | Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7695252 |
| Conte JE et al. | Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. | 1995 | Antimicrob. Agents Chemother. | pmid:7726492 |
| Ménard A et al. | PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:11897613 |
| Ohtani H et al. | Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. | 2000 | Antimicrob. Agents Chemother. | pmid:10991836 |
| Hotomi M et al. | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. | 2007 | Antimicrob. Agents Chemother. | pmid:17698631 |
| Nagai K et al. | Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. | 2001 | Antimicrob. Agents Chemother. | pmid:11600391 |
| Berg HF et al. | Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. | 2004 | Antimicrob. Agents Chemother. | pmid:15504839 |
| Brown BA et al. | Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. | 1992 | Antimicrob. Agents Chemother. | pmid:1317144 |
| Spangler SK et al. | Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8192445 |
| Friedman ND et al. | Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. | 2016 | Antimicrob. Agents Chemother. | pmid:26883709 |
| Bastian S et al. | Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. | 2011 | Antimicrob. Agents Chemother. | pmid:21135185 |
| Luna-Herrera J et al. | Antituberculosis activity of clarithromycin. | 1995 | Antimicrob. Agents Chemother. | pmid:8593004 |
| Ellis LC et al. | Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. | 1995 | Antimicrob. Agents Chemother. | pmid:8593025 |
| Truffot-Pernot C et al. | Clarithromycin is inactive against Mycobacterium tuberculosis. | 1995 | Antimicrob. Agents Chemother. | pmid:8593032 |
| De R et al. | Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. | 2009 | Antimicrob. Agents Chemother. | pmid:19204190 |
| Wolinsky E | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8031406 |
| Ramón-GarcÃa S et al. | Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. | 2011 | Antimicrob. Agents Chemother. | pmid:21576426 |
| Mathis A et al. | Mitochondrial ribosome as the target for the macrolide antibiotic clarithromycin in the helminth Echinococcus multilocularis. | 2005 | Antimicrob. Agents Chemother. | pmid:16048933 |
| Dai G et al. | Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:16048962 |
| Collins LA et al. | Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 | Antimicrob. Agents Chemother. | pmid:9527783 |
| Shinkai M et al. | Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression. | 2006 | Antimicrob. Agents Chemother. | pmid:16641444 |
| Anton E et al. | Randomized Trial of Clarithromycin for Mediterranean Spotted Fever. | 2015 | Antimicrob. Agents Chemother. | pmid:26711765 |
| Klemens SP and Cynamon MH | Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7979271 |
| Ji B et al. | Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. | 2008 | Antimicrob. Agents Chemother. | pmid:18391038 |
| Choi GE et al. | Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. | 2012 | Antimicrob. Agents Chemother. | pmid:22564831 |
| Portaels F et al. | In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9687409 |
| Heifets LB et al. | Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium. | 1992 | Antimicrob. Agents Chemother. | pmid:1416852 |
| Brown BA et al. | Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. | 1992 | Antimicrob. Agents Chemother. | pmid:1416891 |
| Biehle J and Cavalieri SJ | In vitro susceptibility of Mycobacterium kansasii to clarithromycin. | 1992 | Antimicrob. Agents Chemother. | pmid:1416897 |
| Chu SY et al. | Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. | 1992 | Antimicrob. Agents Chemother. | pmid:1489187 |
| Ishikawa C et al. | Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes. | 2009 | Antimicrob. Agents Chemother. | pmid:19258275 |
| Araujo FG et al. | Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. | 1992 | Antimicrob. Agents Chemother. | pmid:1489188 |
| Gan VN et al. | Pharmacokinetics of a clarithromycin suspension in infants and children. | 1992 | Antimicrob. Agents Chemother. | pmid:1489191 |
| Alper CM et al. | Efficacy of clarithromycin treatment of acute otitis media caused by infection with penicillin-susceptible, -intermediate, and -resistant Streptococcus pneumoniae in the chinchilla. | 1996 | Antimicrob. Agents Chemother. | pmid:8843299 |
| Falzari K et al. | In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. | 2005 | Antimicrob. Agents Chemother. | pmid:15793125 |
| Rana KZ et al. | Clarithromycin does not affect phosphorylation of zidovudine in vitro. | 1996 | Antimicrob. Agents Chemother. | pmid:8843311 |
| Burucoa C et al. | T2182C mutation is not associated with clarithromycin resistance in Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:15673794 |
| Bermudez LE et al. | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. | 2007 | Antimicrob. Agents Chemother. | pmid:17296742 |
| Barry AL et al. | In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. | 1988 | Antimicrob. Agents Chemother. | pmid:2840016 |
| Nash KA | Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. | 2001 | Antimicrob. Agents Chemother. | pmid:11353601 |
| Alder JD et al. | Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. | 1998 | Antimicrob. Agents Chemother. | pmid:9736568 |
| Gillum JG et al. | Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. | 1996 | Antimicrob. Agents Chemother. | pmid:8807068 |
| Bernut A et al. | In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. | 2014 | Antimicrob. Agents Chemother. | pmid:24798271 |
| Spyridaki I et al. | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. | 2009 | Antimicrob. Agents Chemother. | pmid:19332671 |
| Weiss S et al. | Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. | 2015 | Antimicrob. Agents Chemother. | pmid:26392505 |
| Parra-Ruiz J et al. | Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. | 2010 | Antimicrob. Agents Chemother. | pmid:20696880 |
| Jones RN et al. | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. | 2010 | Antimicrob. Agents Chemother. | pmid:20660671 |
| Wenisch C et al. | Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry. | 1996 | Antimicrob. Agents Chemother. | pmid:8878577 |
| Koh WJ et al. | Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only. | 2013 | Antimicrob. Agents Chemother. | pmid:23183432 |
| Kosowska-Shick K et al. | Comparative antipneumococcal activities of sulopenem and other drugs. | 2009 | Antimicrob. Agents Chemother. | pmid:19307366 |
| Ji B et al. | Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. | 1994 | Antimicrob. Agents Chemother. | pmid:7872741 |
| Skinner PS et al. | A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. | 1994 | Antimicrob. Agents Chemother. | pmid:7872747 |
| Valero G et al. | Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection. | 1994 | Antimicrob. Agents Chemother. | pmid:7872769 |
| Donati M et al. | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. | 2010 | Antimicrob. Agents Chemother. | pmid:20855744 |
| Piccolomini R et al. | Bacteriostatic and bactericidal in vitro activities of clarithromycin and erythromycin against periodontopathic Actinobacillus actinomycetemcomitans. | 1998 | Antimicrob. Agents Chemother. | pmid:9797240 |
| Patel KB et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891147 |